<DOC>
	<DOCNO>NCT02132429</DOCNO>
	<brief_summary>The primary purpose study evaluate safety tolerability multiple oral dos AMG 333 14 day healthy subject migraine subject . As part secondary objective , study characterize pharmacokinetic ( PK ) profile AMG 333 multiple oral dos healthy subject migraine subject , well characterize effect multiple dos AMG 333 increase blood pressure ( BP ) induce cold pressor test ( CPT ) healthy subject .</brief_summary>
	<brief_title>Phase I , Double-Blind , Placebo , MAD Study Evaluate Safety , Tolerability , PK , PD AMG 333 Healthy Subjects Migraine Subjects</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , ascend multiple-dose study evaluate AMG 333 healthy subject subject migraine . Eight healthy subject enrol cohort 1 5 . Study subject randomize 6 subject receive AMG 333 2 subject receive placebo ( 3:1 ratio ) per cohort . Likewise , 8 migraine subject enrol cohort 6 randomize receive AMG 333 placebo ( 3:1 ratio ) . All subject house 15 day allow return home . Migraine subject self-administer headache diary least daily screen out-patient portion study , site personnel administer headache diary in-house period study . Healthy subject keep headache diary screening headache diary administer site personnel least daily start day 1 day 14 , self administer throughout participation study .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Healthy male female subject ( cohort 1 5 ) male female subject migraine ( cohort 6 ) , ≥ 18 ≤ 55 year age time screening , history evidence clinicallyrelevant medical disorder determine investigator consultation Amgen physician . History evidence clinically significant disorder , condition , disease opinion investigator Amgen physician , would significantly impair pain perception ( eg , history stroke , history neuropathy ) , would pose risk subject safety interfere evaluation , procedure , study completion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Migraine</keyword>
</DOC>